指南与共识心力衰竭与心肌病瓣膜病与结构性心脏病

心力衰竭合并继发性二尖瓣反流的管理:ESC四学会联合立场声明

The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC.
指南 / 共识 · Eur Heart J · 2021-01-01

继发性二尖瓣反流(SMR)在射血分数降低的慢性心衰中常见,由左室重构导致瓣叶对合不良,加重症状并恶化预后。该联合立场声明由ESC下属HFA、EACVI、EHRA和EAPCI共同制定,提出基于心脏团队的多学科评估与管理路径,强调优化药物和器械治疗,并谨慎解读经导管修复随机试验的矛盾结果。

要点

  • SMR常见于HFrEF,与症状进展和不良预后相关。
  • 管理需及时转诊至多学科心脏团队。
  • 优化指南推荐的药物和器械治疗是基础。

核心结论

  • SMR在HFrEF患者中常见,由左室重构导致瓣叶对合不良,加重心衰症状和体征并带来更差预后。
  • 管理复杂,需及时转诊至多学科心脏团队,并基于指南优化药物和器械治疗。
  • 手术矫正SMR证据稀少,是否改善预后存疑;经导管修复是 promising 的替代方案,但当前随机试验结果矛盾需谨慎解读。

研究设计与样本

  • 由ESC下属HFA、EACVI、EHRA和EAPCI四个学会共同制定的联合立场声明。

主要发现

  • SMR由左室重构导致瓣叶对合不良,常见于HFrEF。
  • SMR加重心衰症状和体征,并带来更差预后。
  • 手术矫正SMR证据稀少,是否改善预后存疑。
  • 经导管修复是 promising 的替代方案,但当前随机试验结果矛盾。

关键数值与推荐

  • 需根据指南推荐优化药物和器械治疗。
  • 需进行仔细的临床和影像学评估,关注二尖瓣和左室的解剖与功能特征、整体心衰状态及相关合并症。
  • 管理需基于心脏团队方法。

临床怎么用

  • 对心衰合并SMR患者,应及时转诊至多学科心脏团队。
  • 首先根据指南优化药物和器械治疗。
  • 进行仔细的临床和影像学评估,包括二尖瓣和左室解剖功能、心衰状态及合并症。
  • 手术矫正SMR需谨慎,因证据稀少且预后获益存疑。
  • 经导管修复可作为替代方案,但需谨慎解读随机试验的矛盾结果。

局限性

  • 手术矫正SMR的证据稀少。
  • 经导管修复的当前随机试验结果矛盾,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary (or functional) mitral regurgitation (SMR) occurs frequently in chronic heart failure (HF) with reduced left ventricular (LV) ejection fraction, resulting from LV remodelling that prevents coaptation of the valve leaflets. Secondary mitral regurgitation contributes to progression of the symptoms and signs of HF and confers worse prognosis. The management of HF patients with SMR is complex and requires timely referral to a multidisciplinary Heart Team. Optimization of pharmacological and device therapy according to guideline recommendations is crucial. Further management requires careful clinical and imaging assessment, addressing the anatomical and functional features of the mitral valve and left ventricle, overall HF status, and relevant comorbidities. Evidence concerning surgical correction of SMR is sparse and it is doubtful whether this approach improves prognosis. Transcatheter repair has emerged as a promising alternative, but the conflicting results of current randomized trials require careful interpretation. This collaborative position statement, developed by four key associations of the European Society of Cardiology-the Heart Failure Association (HFA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association of Cardiovascular Imaging (EACVI), and European Heart Rhythm Association (EHRA)-presents an updated practical approach to the evaluation and management of patients with HF and SMR based upon a Heart Team approach.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Coats AJS, Anker SD, Baumbach A, et al. The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur Heart J. 2021. PMID: 33734354. doi:10.1093/eurheartj/ehab086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。